# Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients

> **NCT03030248** · PHASE2 · COMPLETED · sponsor: **Medical College of Wisconsin** · enrollment: 9 (actual)

## Conditions studied

- Clostridium Difficile Infection
- Hematologic Diseases
- Bone Marrow Transplant
- Oncologic Disorders

## Interventions

- **DRUG:** Vancomycin Oral Capsule
- **DRUG:** Placebo Oral Capsule

## Key facts

- **NCT ID:** NCT03030248
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-01
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-06-30
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03030248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03030248, "Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03030248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*